科研成果详情

题名A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
作者
发表期刊JOURNAL OF HEPATOLOGY   影响因子和分区
语种英语
原始文献类型Article
关键词MAFLD Cirrhosis Diagnostic criteria Metabolic NAFLD Steatohepatitis Diabetes Obesity
其他关键词NONALCOHOLIC STEATOHEPATITIS ; HISTOLOGIC FEATURES ; NATURAL-HISTORY ; HEALTHY OBESE ; MANAGEMENT ; DIAGNOSIS ; NAFLD ; PROGRESSION ; PREVALENCE ; PREVENTION
摘要The exclusion of other chronic liver diseases including excess alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, positive criteria to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. We propose that disease assessment and stratification of severity should extend beyond a simple dichotomous classification to steatohepatitis vs. non-steatohepatitis. The group also suggests a set of criteria to define MAFLD-associated cirrhosis and proposes a conceptual framework to consider other causes of fatty liver disease. Finally, we bring clarity to the distinction between diagnostic criteria and inclusion criteria for research studies and clinical trials. Reaching consensus on the criteria for MAFLD will help unify the terminology (e.g. for ICD-coding), enhance the legitimacy of clinical practice and clinical trials, improve clinical care and move the clinical and scientific field of liver research forward. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
资助项目Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney; National Health and Medical Research Council of Australia (NHMRC)National Health and Medical Research Council of Australia [APP1053206, APP1149976, APP1107178, APP1108422]; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust; University of Birmingham
出版者ELSEVIER
出版地AMSTERDAM
ISSN0168-8278
EISSN1600-0641
卷号73期号:1页码:202-209
DOI10.1016/j.jhep.2020.03.039
WOS类目Gastroenterology & Hepatology
WOS研究方向Gastroenterology & Hepatology
WOS记录号WOS:000563494500023
收录类别SCIE ; PUBMED ; SCOPUS
发表日期2020-07
URL查看原文
Pubmed记录号32278004
Scopus记录号2-s2.0-85083788691
ESI热点论文2020-09 ; 2020-11 ; 2021-03 ; 2021-05 ; 2021-07 ; 2021-09 ; 2021-11 ; 2022-01 ; 2022-03 ; 2022-07 ; 2022-09
ESI高被引论文2020-09 ; 2020-11 ; 2021-01 ; 2021-03 ; 2021-05 ; 2021-07 ; 2021-11 ; 2022-01 ; 2022-03 ; 2022-07 ; 2022-09 ; 2022-11 ; 2023-01 ; 2023-03 ; 2023-05 ; 2023-07 ; 2023-09 ; 2023-11 ; 2024-01 ; 2024-03 ; 2024-05
自科自定义期刊分类T2(B)类
引用统计
被引频次:1076[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/20913
专题附属第一医院
通讯作者Eslam, Mohammed; Newsome, Philip N.; Ratziu, Vlad; George, Jacob
作者单位
1.Westmead Hosp, Storr Liver Ctr, Westmead Inst Med Res, Westmead, NSW 2145, Australia;
2.Univ Sydney, Westmead, NSW 2145, Australia;
3.Univ Hosp Birmingham NHS Fdn Trust, Natl Inst Hlth Res Biomed Res Ctr, Birmingham, W Midlands, England;
4.Univ Birmingham, Birmingham, W Midlands, England;
5.Univ Birmingham, Ctr Liver & Gastrointestinal Res, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England;
6.Univ Hosp Birmingham NHS Fdn Trust, Liver Unit, Birmingham, W Midlands, England;
7.Inst Liver & Biliary Sci, Dept Hepatol, New Delhi, India;
8.Newcastle Univ, Translat & Clin Res Inst, Fac Med Sci, Newcastle Upon Tyne, Tyne & Wear, England;
9.Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle NIHR Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England;
10.Univ Verona, Dept Med, Sect Endocrinol Diabet & Metab, Verona, Italy;
11.Azienda Osped Univ Integrata Verona, Verona, Italy;
12.Univ Seville, Virgen del Rocio Univ Hosp, Inst Biomed Sevilla, CIBEREHD,UCM Digest Dis, Seville, Spain;
13.Univ Haifa, Sch Publ Hlth, Haifa, Israel;
14.Tel Aviv Med Ctr & Sch Med, Dept Gastroenterol, Tel Aviv, Israel;
15.Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China;
16.Univ Bern, Univ Clin Visceral Surg & Med, Inselspital, Bern, Switzerland;
17.Univ Bern, Dept Biomed Res, Bern, Switzerland;
18.Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med, Mainz, Germany;
19.Kurume Univ, Dept Med, Div Gastroenterol, Sch Med, Kurume, Fukuoka, Japan;
20.Pontificia Univ Catolica Chile, Dept Gastroenterol, Escuela Med, Santiago, Chile;
21.Pontificia Univ Catolica Chile, Ctr Envejecimiento & Regenerac CARE, Dept Biol Celular & Mol, Fac Ciencias Biol, Santiago, Chile;
22.Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy;
23.Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Transfus Med & Hematol, Translat Med, Milan, Italy;
24.Mansoura Univ, Fac Med, Internal Med Dept, Hepatol & Gastroenterol Unit, Mansoura, Egypt;
25.Italian Liver Fdn, Liver Ctr, Trieste, Italy;
26.Univ Helsinki, Dept Med, Helsinki, Finland;
27.Helsinki Univ Hosp, Helsinki, Finland;
28.Minerva Fdn, Helsinki, Finland;
29.Shanghai Jiao Tong Univ, Ctr Fatty Liver, Dept Gastroenterol, Xin Hua Hosp,Sch Med,Shanghai Key Lab Pediat Gast, Shanghai, Peoples R China;
30.Aarhus Univ Hosp, Dept Hepatol & Gastroenterol, Aarhus, Denmark;
31.Marmara Univ, Sch Med, Dept Gastroenterol, Istanbul, Turkey;
32.Marmara Univ, Inst Gastroenterol, Istanbul, Turkey;
33.Univ Lisbon, Clin Univ Gastrenterol, Fac Med, Lab Nutr, Lisbon, Portugal;
34.Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil;
35.Paris Diderot Univ, Dept Pathol Physiol & Imaging, Beaujon Hosp, Paris, France;
36.Univ Western Australia, Sir Charles Gairdner Hosp Unit, Med Sch, Nedlands, WA, Australia;
37.Wenzhou Med Univ, Affiliated Hosp 1, NAFLD Res Ctr, Dept Hepatol, Wenzhou, Peoples R China;
38.Wenzhou Med Univ, Inst Hepatol, Wenzhou, Peoples R China;
39.Minia Univ Hosp, Fac Med, Dept Gastroenterol Hepatol & Endem Med, Al Minya, Egypt;
40.Univ Malaya, Fac Med, Dept Med, Gastroenterol & Hepatol Unit, Kuala Lumpur, Malaysia;
41.Univ Nacl Autonoma Mexico, Med Sur Clin & Fdn, Liver Res Unit, Mexico City, DF, Mexico;
42.Univ Nacl Autonoma Mexico, Fac Med, Mexico City, DF, Mexico;
43.Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea;
44.Univ Paris VII, Ctr Rech Inflammat, Inserm Umr 1149, Paris, France;
45.Univ Turin, Dept Med Sci, Div Gastroenterol & Hepatol, Turin, Italy;
46.Sorbonne Univ, Inst Cardiometab & Nutr ICAN, Hop Pitie Salpetriere, AP HP, Paris, France
推荐引用方式
GB/T 7714
Eslam, Mohammed,Newsome, Philip N.,Sarin, Shiv K.,et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. JOURNAL OF HEPATOLOGY,2020,73(1):202-209.
APA Eslam, Mohammed., Newsome, Philip N.., Sarin, Shiv K.., Anstee, Quentin M.., Targher, Giovanni., ... & George, Jacob. (2020). A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. JOURNAL OF HEPATOLOGY, 73(1), 202-209.
MLA Eslam, Mohammed,et al."A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement".JOURNAL OF HEPATOLOGY 73.1(2020):202-209.

条目包含的文件

条目无相关文件。
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Eslam, Mohammed]的文章
[Newsome, Philip N.]的文章
[Sarin, Shiv K.]的文章
百度学术
百度学术中相似的文章
[Eslam, Mohammed]的文章
[Newsome, Philip N.]的文章
[Sarin, Shiv K.]的文章
必应学术
必应学术中相似的文章
[Eslam, Mohammed]的文章
[Newsome, Philip N.]的文章
[Sarin, Shiv K.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。